"Antibodies go Molecular" Abazyme provides custom research services to the life science market. Our focus is on recombinant monoclonal antibodies. We use our proprietary ACE ™ technology allows us to create fully sequenced and functional antibodies in less time than it typically takes to develop hybridomas. Recombinant antibodies, unlike hybridomas, can be fine-tuned through molecular engineering. They are also extremely stable and don't require liquid nitrogen storage. Along with your antibody, you also get its sequence and stable expression vector which can be used to produce additional antibody in a widely used mammalian cell line. We also offer custom assay development, production services and antigen optimization. We were voted "highest impact" life science company by MassChallenge.org. due to our ACE tm approach. We've walked in our customer's shoes; we understand how frustrating it can be to get cost-effective antibody reagents in a time-frame that makes sense for R&D. We're building better antibodies, so our customers can succeed at moving their science forward. Call us at 775-363-3329 to discuss how we can be your antibody partner.
View Top Employees from AbazymeWebsite | http://www.abazyme.com |
Revenue | $3 million |
Employees | 1 (1 on RocketReach) |
Founded | 2005 |
Address | 767C Concord Ave, Cambridge, Massachusetts 02137, US |
Industry | Biotechnology, Business Services General, Business Services, Science and Engineering, Health Care, Information Technology, Pharmaceutical |
Competitors | Anchor Therapeutics, FORUM Pharmaceuticals, Pfizer, Visgo Therapeutics, Inc., Xalud Therapeutics, Inc. |
SIC | SIC Code 38 Companies, SIC Code 384 Companies |
NAICS | NAICS Code 33 Companies, NAICS Code 339 Companies |
Looking for a particular Abazyme employee's phone or email?
The Abazyme annual revenue was $3 million in 2024.
Jim Dasch is the Owner of Abazyme.
1 people are employed at Abazyme.
Abazyme is based in Cambridge, Massachusetts.
The NAICS codes for Abazyme are [33, 339].
The SIC codes for Abazyme are [38, 384].